BMS seeds the oyster as it strikes Asian oncology deal with ASLAN
This article was originally published in Scrip
Executive Summary
The private Asian drug development venture ASLAN Pharmaceuticals has signed its first product licensing deal with Big Pharma, acquiring rights in selected Asian markets to an investigational anticancer discovered by Bristol-Myers Squibb.